What are the indications for finerenone (Kerendia) and how should it be dosed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Finerenone Indications and Dosing

Finerenone is indicated for adults with type 2 diabetes and chronic kidney disease (eGFR >25 mL/min/1.73 m² with albuminuria >30 mg/g) despite maximum tolerated RAS inhibitor therapy, and for adults with heart failure and LVEF ≥40%. 1, 2

Primary Indications

1. Chronic Kidney Disease Associated with Type 2 Diabetes

Finerenone reduces the risk of:

  • Sustained eGFR decline
  • End-stage kidney disease
  • Cardiovascular death
  • Non-fatal myocardial infarction
  • Hospitalization for heart failure 2

Eligibility criteria:

  • Adults with type 2 diabetes
  • eGFR >25 mL/min/1.73 m²
  • Albuminuria >30 mg/g (>3 mg/mmol) despite maximum tolerated RAS inhibitor
  • Normal serum potassium concentration 1

The 2024 KDIGO guidelines specifically recommend nonsteroidal MRAs for patients at high risk of CKD progression and cardiovascular events, demonstrated by persistent albuminuria despite other standard-of-care therapies including SGLT2 inhibitors and RAS inhibitors 1. The pooled FIDELITY analysis (N=13,171) demonstrated a 14% reduction in composite cardiovascular outcomes and 23% reduction in composite kidney outcomes across the spectrum of CKD severity 3.

2. Heart Failure with LVEF ≥40%

Finerenone reduces the risk of:

  • Cardiovascular death
  • Hospitalization for heart failure
  • Urgent heart failure visits 2

This indication was added in 2025 based on the FINEARTS-HF trial, extending finerenone's benefits beyond diabetic kidney disease to heart failure with preserved or mildly reduced ejection fraction 2.

Dosing Algorithm

Initial Dose Selection (Based on eGFR and Potassium)

Before initiating:

  • Confirm serum potassium ≤4.8 mmol/L (or ≤5.0 mmol/L per FDA label) 1, 4
  • Measure baseline eGFR 1

Starting dose:

  • eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
  • eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily 1, 5, 2

Dose Titration (After 4 Weeks)

For CKD with Type 2 Diabetes:

  • Target dose: 20 mg once daily
  • Increase from 10 mg to 20 mg if:
    • Serum potassium ≤4.8 mmol/L
    • eGFR remains stable 3, 6, 5

For Heart Failure with LVEF ≥40%:

  • Target dose: 20 mg or 40 mg once daily (based on eGFR and potassium thresholds) 2

Ongoing Monitoring and Dose Adjustments

Potassium monitoring schedule:

  • At 1 month after initiation
  • At 1 month after any dose change
  • Every 4 months during maintenance therapy 1

Management based on potassium levels:

Potassium Level Action
≤4.8 mmol/L Continue current dose or uptitrate to 20 mg if on 10 mg
4.9-5.5 mmol/L Continue current dose; monitor potassium every 4 months
>5.5 mmol/L Hold finerenone; adjust diet/medications; recheck potassium; restart at 10 mg when potassium ≤5.0 mmol/L

1

Administration Details

  • Timing: Once daily, with or without food 2
  • Continuation: Can be continued even if eGFR falls below 25 mL/min/1.73 m² as long as potassium is acceptable and drug is tolerated 4

Critical Contraindications

Absolute contraindications:

  • Concomitant use with strong CYP3A4 inhibitors (e.g., itraconazole, ketoconazole, ritonavir, clarithromycin)
  • Adrenal insufficiency
  • Hypersensitivity to any component 2

Avoid:

  • Grapefruit or grapefruit juice
  • Strong or moderate CYP3A4 inducers 2

Clinical Context and Positioning

Finerenone is most appropriate as add-on therapy to foundational treatments including RAS inhibitors and SGLT2 inhibitors 1. The 2025 ADA/Diabetes Care guidelines note that finerenone can be used interchangeably with or in addition to SGLT2 inhibitors for slowing CKD progression and providing cardiovascular protection, though there have been no direct head-to-head comparisons 3.

Common Pitfalls to Avoid

  1. Hyperkalemia management: The most common reason for discontinuation (1.2% in FIGARO-DKD) is hyperkalemia, but this is predictable and manageable through dietary modifications, medication adjustments, and dose reduction rather than immediate discontinuation 3, 6, 5

  2. Drug interactions: Monitor closely when initiating moderate or weak CYP3A4 inhibitors; check potassium more frequently during these transitions 2

  3. Patient selection: Exclude patients with heart failure with reduced ejection fraction and uncontrolled hypertension, as these were exclusion criteria in pivotal trials 3, 6

  4. Baseline requirements: Do not initiate if baseline potassium >4.8 mmol/L or eGFR <25 mL/min/1.73 m² 1, 4

The evidence demonstrates that finerenone provides significant cardiorenal protection with a lower risk of hyperkalemia compared to steroidal MRAs like spironolactone, making it a valuable addition to the treatment armamentarium for patients with diabetic kidney disease and heart failure with preserved ejection fraction 3, 6, 1.

Related Questions

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.